Innovative Patents Granted to Catheter Precision, Inc. Expand Portfolio
Significant Patent Advancements for Catheter Precision, Inc.
Catheter Precision, Inc. (VTAK - NYSE/American), a leading medical device company specializing in advanced technologies for cardiac electrophysiology, is thrilled to announce an exciting development in its intellectual property portfolio. The United States Patent and Trademark Office has approved two pivotal patents, strengthening the company's innovative capabilities in this crucial sector.
Understanding the New Patents
The first patent focuses on “Methods of Ventricular Arrhythmia Localization Using a 3D Model.” This remarkable innovation further solidifies the VIVO technology portfolio. It will benefit from the collaboration with Kardionav, a joint venture aimed at enhancing cardiac ventilatory therapies by applying advanced methodologies.
Furthermore, the second patent, “Neurostimulation Devices and Methods,” targets enhancements in cardiac ventricular functions, particularly among patients suffering from heart failure. This initiative will be part of Cardionomix, a subsidiary that aims to provide state-of-the-art heart failure therapies through specific nerve stimulation techniques. This patent represents a crucial step in addressing the complexities associated with cardiac health.
CEO Insights on Patent Approvals
David Jenkins, the CEO of Catheter Precision, expressed his enthusiasm regarding the newly acquired patents. He stated, “We are excited that our intellectual property is being recognized with these patent approvals. Each grant is a testament to the value and uniqueness of our technological advancements in the competitive market of medical devices.” This affirming acknowledgment is projected to reinforce the company's determination to innovate continuously and create impactful solutions.
Overview of VIVO Technology
About VIVO™
VIVO (View Into Ventricular Onset) is Catheter Precision's groundbreaking non-invasive 3D imaging system. It empowers healthcare professionals by allowing them to identify the origins of ventricular arrhythmias before procedures, thus streamlining clinical workflows and reducing procedural timelines. Notably, VIVO has obtained marketing clearance from the U.S. FDA and carries the CE Mark, signifying its compliance with international health and safety standards.
About Catheter Precision, Inc.
About Catheter Precision
As a pioneering player in the medical device industry, Catheter Precision is dedicated to introducing innovative solutions aimed at enhancing cardiac arrhythmia treatments. The company’s focus lies in developing cutting-edge technologies for electrophysiology procedures by working closely with medical professionals and continuously refining its product line.
Future Outlook and Growth Potential
The recent patent grants mark just the beginning of a wider vision for Catheter Precision. The company is adamant about expanding its portfolio and pursuing additional applications to cater to complex cardiac conditions. With ongoing research and development, notable expectations for future technologies and treatments are on the horizon.
Frequently Asked Questions
What are the new patents by Catheter Precision?
Catheter Precision has received patents for methods of ventricular arrhythmia localization and neurostimulation devices aimed at improving heart function.
How does VIVO technology enhance procedures?
VIVO technology allows physicians to identify the source of ventricular arrhythmias pre-procedure, which streamlines workflow and reduces procedure time.
Who is the CEO of Catheter Precision?
The current CEO of Catheter Precision is David Jenkins, who emphasizes the importance of continuous innovation.
What does Cardionomix focus on?
Cardionomix, a subsidiary of Catheter Precision, is focused on heart failure therapies using advanced neurostimulation techniques.
What is the goal of Catheter Precision?
The primary goal of Catheter Precision is to develop innovative medical devices that improve the treatment of cardiac arrhythmias through collaboration and technology advancement.
About The Author
Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
